Navigation Links
Oncothyreon appoints Scott Peterson as Vice President of Research and Development

SEATTLE, June 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Scott Peterson, Ph.D., as Vice President, Research and Development at Oncothyreon. In this position, Dr. Peterson will be responsible for overseeing those pre-clinical and non-clinical research and development activities that will support the advancement of the Company's pipeline of oncology product candidates into late phase clinical trials.

"Scott brings an extensive background in cancer drug development to his new role at Oncothyreon," said Robert L. Kirkman, M.D, President and Chief Executive Officer. "His prior experience in small molecule drug development includes work with protein kinases that will be especially relevant to PX-866, our inhibitor of PI-3 kinase for which we recently presented encouraging preliminary Phase 1 data at the American Society of Clinical Oncology. His broad knowledge of cancer biology and drug targets will also be helpful in our ongoing search for new product candidates. We are delighted to have him join our team."

"I am very pleased to join Oncothyreon and excited about the opportunity to contribute to the further development of the Company's intriguing pipeline of targeted anti-cancer drug candidates," said Dr. Peterson. "I believe Oncothyreon's diverse pipeline of therapeutic vaccines, such as Stimuvax(R), and targeted small molecules, including PX-866 and PX-478, create multiple opportunities for future success. I am looking forward to contributing to that future."

Dr. Peterson joins Oncothyreon from Zymogenetics, Inc., Seattle, Washington, where he has served as Director and Department Head, Oncology Research, since 2007. In that capacity he has led a group of scientists engaged in antibody target discovery and drug candidate identification in oncology. From 1999 until 2007 he held a variety of positions at ICOS Corporation in Bothell, Washington, most recently as a Principal Scientist in Oncology Drug Discovery. At ICOS he was involved in both small molecule and antibody development. Dr. Peterson will assume his new role at Oncothyreon on August 1, 2009.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to future preclinical and clinical development plans for our product candidates. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of our product candidates, and the indications for which our product candidates might be developed. There can be no guarantee that the results of preclinical studies or clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Oncothyreon announces closing of $11.1 million registered direct financing
3. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
4. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
5. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
6. Oncothyreon reports first quarter 2009 financial results
7. Oncothyreon regains compliance with NASDAQ listing requirements
8. Oncothyreon to present at Invest Northwest 2009
9. Oncothyreon reports full year and fourth quarter 2008 financial results
10. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
11. Oncothyreon to present at BIO CEO & Investor Conference 2009
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):